Using AI to Detect Heart Failure
Every 56 seconds, someone dies from cardiovascular disease. Chronic lung disease, meanwhile, is the world's third-leading cause of death.
As with many illnesses, the key to saving lives is to identify it and take action early. That’s what Vironix was designed to do.
This medical technology company makes Artificial Intelligence-enabled therapeutic monitoring software. This helps doctors catch and intervene early on dangerous health episodes.
Vironix’s patent-pending software outperforms the current standard of care in detecting/triaging heart failure, COPD, and asthma flareups. The company completed the 2021 Mass Challenge Accelerator and has Letters of Intent that represent a $150 million annual revenue opportunity.
Just enter your e-mail address below & get this guide instantly
No thanks, I’d like to continue making next to nothing in the stock market.
